<DOC>
	<DOCNO>NCT00436501</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose VEGF Trap give together docetaxel see well work treat patient persistent recurrent ovarian epithelial cancer , primary peritoneal cancer , fallopian tube cancer . VEGF Trap may stop growth tumor cell block blood flow tumor . Drugs use chemotherapy , docetaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving VEGF Trap together docetaxel may kill tumor cell</brief_summary>
	<brief_title>VEGF Trap Docetaxel Treating Patients With Persistent Recurrent Ovarian Epithelial Cancer , Primary Peritoneal Cancer , Fallopian Tube Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine safety tolerability VEGF Trap docetaxel patient persistent recurrent ovarian epithelial , primary peritoneal , fallopian tube cancer . ( Phase I [ close accrual 3/14/2008 ] ) II . Determine maximum tolerate dose VEGF Trap patient . ( Phase I [ close accrual 3/14/2008 ] ) III . Determine pharmacokinetics VEGF Trap administer alone combination docetaxel patient . ( Phase I [ close accrual 3/14/2008 ] ) IV . Determine effect VEGF Trap tumor perfusion metabolism patient . ( Phase I [ close accrual 3/14/2008 ] ) V. Determine effect VEGF Trap docetaxel circulate endothelial precursor circulate endothelial cell patient . ( Phase I [ close accrual 3/14/2008 ] ) VI . Determine frequency clinical response ( partial response complete response ) patient treat regimen . ( Phase II [ open accrual 5/9/2008 ] ) VII . Determine progression-free survival ( PFS ) overall survival ( OS ) patient treat regimen . ( Phase II [ open accrual 5/9/2008 ] ) SECONDARY OBJECTIVES : I . Determine duration PFS OS patient treat regimen . ( Phase II ) II . Determine frequency severity adverse effect regimen patient . ( Phase II ) III . Determine proportion patient PFS 6 month . ( Phase II ) OUTLINE : This multicenter , phase I , dose-escalation study VEGF Trap follow phase II study . PHASE I ( close accrual 3/14/2008 ) : Patients receive VEGF Trap IV 1 hour day 1 course 1 . Patients receive VEGF Trap IV 1 hour docetaxel IV 1 hour day 1 subsequent course . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos VEGF Trap maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . PHASE II ( open accrual 5/9/2008 ) : Patients receive VEGF Trap MTD determine phase I docetaxel phase I . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients enrol phase I ( close accrual 3/14/2008 ) undergo blood sample collection periodically pharmacokinetic study surrogate marker study . These patient also undergo dynamic contrast-enhanced MRI , fludeoxyglucose F 18 positron emission tomography , CT scan baseline day 1 course 1 2 evaluate blood flow parameter metabolic activity tumor . Patients enrol phase I ( close accrual 3/14/2008 ) phase II also undergo blood collection Anti-VEGF trap antibody . After completion study treatment , patient follow 1 2 month periodically thereafter .</detailed_description>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Criteria : Histologically confirm ovarian epithelial , primary peritoneal , fallopian tube cancer : Persistent recurrent disease Measurable disease , define &gt; = 1 unidimensionally measurable lesion &gt; = 20 mm conventional technique : Must &gt; = 1 target lesion assess response ; Tumors within previously irradiate field consider nontarget lesion Must receive 1 prior platinumbased chemotherapy regimen ( primary disease ) contain carboplatin , cisplatin , organoplatinum compound : Initial treatment may include following : Highdose therapy ; Consolidation therapy ; Extended therapy administer surgical nonsurgical assessment AND Must receive 1 prior platinumbased chemotherapy regimen ( primary disease ) contain carboplatin , cisplatin , organoplatinum compound : One additional cytotoxic regimen recurrent persistent disease allow No history evidence CNS disease , include primary brain tumor brain metastasis Zubrod performance status 02 ( 01 patient receive 2 prior regimen [ taxane and/or platinum regimen count separately ] ) Absolute neutrophil count &gt; = 1,500/mm^3 Platelet count &gt; = 100,000/mm^3 Hemoglobin &gt; = 9 g/dL Bilirubin normal aspartate aminotransferase / alanine aminotransferase ( AST/ALT ) &lt; 2.5 time upper limit normal ( ULN ) Creatinine &lt; 1.5 time ULN OR creatinine clearance &gt; 60 mL/min Prothrombin Time ( PT ) /international normalize ratio ( INR ) &lt; 1.5 OR inrange INR 23 ( patient stable dose therapeutic warfarin low molecular weight heparin ) PTT &lt; 1.2 time control Urine protein : creatinine ratio &lt; 1 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 6 month completion study treatment No active infection require antibiotic No sensory motor neuropathy &gt; = grade 2 No history allergic reaction attribute compound similar chemical biologic composition VEGF Trap , Magnevist , fludeoxyglucose F 18 No history allergic reaction paclitaxel docetaxel product mixed Cremophor EL Tween 80 No active bleed pathologic condition would carry high risk bleeding , include follow : Known bleed disorder ; Coagulopathy ; Peptic ulcer disease ; Diverticulitis ; Tumor involve major vessel No active and/or untreated pulmonary embolism , deep vein thrombosis , thromboembolic event ( i.e. , condition associate aberrant clot migration induce clot ) No history evidence CNS disease , include follow : Seizures control standard medical therapy ; Cerebrovascular accident ; Transient ischemic attack ; Subarachnoid hemorrhage within past 6 month No clinically significant cardiovascular disease , include follow : Uncontrolled hypertension ( i.e. , systolic blood pressure [ BP ] &gt; 150 mm Hg diastolic BP &gt; 100 mm Hg ; systolic BP &gt; 180 mm Hg diastolic BP &lt; 90 mm Hg OR diastolic BP &gt; 90 mm Hg &gt; = 2 measurement within past 3 month ) ; Myocardial infarction ; Coronary peripheral artery bypass graft No clinically significant cardiovascular disease , include follow : New York Heart association class III IV congestive heart failure ; Serious cardiac arrhythmia require medication ; Peripheral vascular disease &gt; = grade 2 ; Unstable angina within past 6 month ; Clinically significant peripheral artery disease ( e.g. , claudication ) within past 6 month No known hypersensitivity Chinese hamster ovary cell product recombinant human humanize antibody Able undergo MRI scan : No claustrophobia ; No implant device metallic foreign body compatible MRI ( e.g. , ferromagnetic implant pacemaker ) ; No known history allergic reaction gadolinium contrast agents No invasive malignancy within past 5 year except nonmelanoma skin cancer No significant traumatic injury within past 28 day Recovered prior therapy NCI Common Terminology Criteria Adverse Events ( CTCAE ) version 3.0 grade = &lt; 1 : Alopecia allow No prior VEGF Trap No prior cancer treatment would preclude study treatment Prior paclitaxel allow Prior docetaxel primary recurrent disease allow provide follow criterion meet : No disease progression therapy ; No disease relapse within 3 month complete therapy ; No persistent disease completion primary therapy More 7 day since prior placement vascular access device core biopsy At least 1 week since prior hormonal therapy malignant tumor At least 4 week since prior therapy , include immunologic agent ( 6 week nitrosoureas mitomycin C ) More 28 day since prior major surgery , open biopsy , dental extraction , dental surgery/procedure result open wound No concurrent major surgery No concurrent combination antiretroviral therapy HIVpositive patient No concurrent anticancer therapy No concurrent investigational agent No concurrent hematopoietic growth factor course 1 phase I Concurrent hormone replacement therapy allow White blood count ( WBC ) &gt; = 3,000/mm^3</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>primary peritoneal cavity cancer</keyword>
	<keyword>Ovarian Epithelial Cancer</keyword>
	<keyword>Peritoneal Cancer</keyword>
	<keyword>Fallopian Tube Cancer</keyword>
	<keyword>VEGF Trap</keyword>
	<keyword>aflibercept</keyword>
	<keyword>vascular endothelial growth factor trap</keyword>
	<keyword>Zaltrap</keyword>
	<keyword>docetaxel</keyword>
	<keyword>RP 56976</keyword>
	<keyword>Taxotere</keyword>
	<keyword>TXT</keyword>
</DOC>